Envestnet Asset Management Inc Travere Therapeutics, Inc. Transaction History

Envestnet Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	BUY	$15.3 - $22.61 $11,230 - $16,595	734 Added 7.37%	10,695 $164,000
Q1 2023 May 11, 2023	BUY	$17.82 - $22.89 $177,505 - $228,007	9,961 New	9,961 $224,000
Q3 2022 Nov 10, 2022	BUY	$22.91 - $28.63 $3,115 - $3,893	136 Added 1.38%	10,025 $247,000
Q2 2022 Aug 03, 2022	SELL	$20.94 - $30.01 $9,904 - $14,194	-473 Reduced 4.56%	9,889 $240,000
Q1 2022 May 04, 2022	BUY	$23.61 - $30.6 $28,898 - $37,454	1,224 Added 13.39%	10,362 $267,000
Q4 2021 Feb 04, 2022	BUY	$24.34 - $31.17 $4,162 - $5,330	171 Added 1.91%	9,138 $284,000
Q3 2021 Oct 07, 2021	BUY	$12.98 - $25.03 $116,391 - $224,444	8,967 New	8,967 $217,000

198

84.9M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.